Bergmann Ingo, Szabanowski Torsten, Bräuer Anselm, Crozier Thomas A, Bauer Martin, Hinz José Maria
Department of Anaesthesiology, Emergency and Intensive Care Medicine, University of Göttingen Medical School, Robert-Koch Str. 40, 37075 Göttingen, Germany.
BMC Anesthesiol. 2015 Jan 18;15(1):3. doi: 10.1186/1471-2253-15-3. eCollection 2015.
Even extremely high-doses of the potent opioid, sufentanil, cannot reliably suppress stress responses to intense surgical stimuli such as sternotomy. The chemically related opioid remifentanil with its different pharmacokinetics and binding affinities for delta- and kappa-opioid receptors might be more effective in attenuating these responses.
ASA I-III patients scheduled for a surgical procedure with sternotomy under balanced anesthesia (sevoflurane and sufentanil 3 μg.kg(-1) bolus, 0.017 μg.kg(-1).min(-1) infusion) were randomized into two groups. Patients in the study group were supplemented with remifentanil (2 μg.kg(-1) bolus, 2-7 μg.kg(-1).min(-1) infusion) starting ten minutes before sternotomy. Heart rate, arterial blood pressures, cardiac index, ejection fraction, systemic vascular resistance index (SVRI), total body oxygen uptake (VO2) and electric dermal response were measured and compared between the groups.
62 patients were studied (study group 32, control group 30). Systolic and mean arterial blood pressures, SVRI, VO2 and skin conductance increased during sternotomy and sternal spread in the control group but not in the study group. Systolic blood pressure increase: 7.5 ± 19 mmHg vs. -3.4 ± 8.9 (p = 0.005); VO2 increase: 31 ± 46% vs. -0.4 ± 32%; incidence of systolic blood pressure increase greater than 15 percent: 20% vs. 3% (p = 0.035) (control vs. study group).
High-dose remifentanil added to sevoflurane-sufentanil anesthesia suppresses the sympathoadrenergic response to sternotomy and sternal spread better than high-dose sufentanil alone.
DRKS00004327, August 31, 2012.
即使是极高剂量的强效阿片类药物舒芬太尼,也无法可靠地抑制对诸如胸骨切开术等强烈手术刺激的应激反应。化学结构相关的阿片类药物瑞芬太尼,因其不同的药代动力学以及对δ和κ阿片受体的结合亲和力,可能在减弱这些反应方面更有效。
计划在平衡麻醉(七氟醚和3μg.kg⁻¹负荷剂量舒芬太尼,0.017μg.kg⁻¹.min⁻¹输注)下行胸骨切开术的美国麻醉医师协会(ASA)Ⅰ-Ⅲ级患者被随机分为两组。研究组患者在胸骨切开术前10分钟开始补充瑞芬太尼(2μg.kg⁻¹负荷剂量,2 - 7μg.kg⁻¹.min⁻¹输注)。测量并比较两组患者的心率、动脉血压、心脏指数、射血分数、全身血管阻力指数(SVRI)、全身氧摄取量(VO₂)和皮肤电反应。
共研究62例患者(研究组32例,对照组30例)。对照组在胸骨切开术和胸骨撑开期间收缩压、平均动脉压、SVRI、VO₂和皮肤电导增加,而研究组未增加。收缩压升高:7.5±19mmHg对比-3.4±8.9(p = 0.005);VO₂升高:31±46%对比-0.4±32%;收缩压升高大于15%的发生率:20%对比3%(p = 0.035)(对照组对比研究组)。
七氟醚-舒芬太尼麻醉中添加高剂量瑞芬太尼比单独使用高剂量舒芬太尼能更好地抑制对胸骨切开术和胸骨撑开的交感肾上腺能反应。
DRKS00004327,2012年8月31日。